Last reviewed · How we verify
Maintenance Therapy with Capecitabine
Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.
Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth. Used for Maintenance therapy for colorectal cancer (likely indication based on capecitabine use), Metastatic breast cancer, Gastric cancer.
At a glance
| Generic name | Maintenance Therapy with Capecitabine |
|---|---|
| Sponsor | Jiangxi Provincial Cancer Hospital |
| Drug class | Fluoropyrimidine antimetabolite |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Capecitabine is an oral fluoropyrimidine carbamate that undergoes hepatic and tumor-selective conversion to 5-fluorouracil (5-FU). Once activated, 5-FU inhibits thymidylate synthase, blocking dTMP synthesis and DNA replication, while also incorporating into RNA to disrupt protein synthesis. This dual mechanism leads to cancer cell death, particularly in rapidly dividing cells.
Approved indications
- Maintenance therapy for colorectal cancer (likely indication based on capecitabine use)
- Metastatic breast cancer
- Gastric cancer
Common side effects
- Hand-foot skin reaction
- Diarrhea
- Nausea
- Fatigue
- Vomiting
- Stomatitis
- Myelosuppression
Key clinical trials
- Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (PHASE3)
- A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT) (PHASE2)
- A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer (PHASE2)
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer (PHASE3)
- Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC (PHASE1, PHASE2)
- A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma (PHASE2)
- CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer (PHASE2)
- TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: